🧠This Week in Neuroscience: PTSD Treatment, MS Stem Cell Therapy and More
Stay informed with the latest neuroscience breakthroughs! In this week’s roundup, we highlight key updates in multiple sclerosis, PTSD treatment, MPS II, and migraine management. From new patents and FDA designations to exciting partnerships and funding, this episode covers the most significant developments in neuroscience.
In Today’s Newsletter
🧠Silo Pharma Secures Australian Patent for PTSD Treatment SPC-15 [1] [3 September 2025]
Source: GlobeNewswire
Context: Silo Pharma has been granted a patent for SPC-15, an intranasal PTSD treatment developed with Columbia University.
Key Point: This patent strengthens Silo’s intellectual property portfolio for its lead asset and supports clinical trials for PTSD.
Implication: The patent could help bring a novel PTSD treatment to market, offering new options for patients.
🌱 Hope Biosciences Receives FDA RMAT Designation for Stem Cell Therapy in MS [2] [4 September 2025]
Source: Multiple Sclerosis News Today
Context: Hope Biosciences’ adipose-derived mesenchymal stem cells (HB-adMSCs) for relapsing-remitting multiple sclerosis (RRMS) have received the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation.
Key Point: This is the first RMAT designation for an MS treatment, facilitating faster FDA approval.
Implication: The RMAT designation could speed up the approval process, offering a promising new stem cell therapy for MS patients.
đź’¸ Polpharma Biologics & MS Pharma Expand MS Biosimilars in MENA [3] [2 September 2025]
Source: Business Wire
Context: Polpharma Biologics signs licensing agreements with MS Pharma to commercialize MS biosimilars (vedolizumab, ocrelizumab, guselkumab) in the MENA region.
Key Point: MS Pharma will be responsible for marketing and distribution, while Polpharma handles manufacturing and supply.
Implication: This collaboration could expand access to affordable MS therapies in the MENA region.
đź’Š Zydus and Synthon Partner for Ozanimod Capsules in MS [4] [5 September 2025]
Source: PR Newswire
Context: Zydus Lifesciences and Synthon BV enter an agreement to bring Ozanimod Capsules (generic ZEPOSIA®) for MS to the U.S. market.
Key Point: The agreement positions Synthon for regulatory approval, while Zydus handles commercialization in the U.S.
Implication: This partnership offers a more affordable treatment option for MS patients, increasing accessibility to vital therapies.
🧪 Octave Bioscience Announces $35M Series C Financing to Accelerate MSDA Test & Other Initiatives [5] [4 September 2025]
Source: Business Wire
Context: Octave Bioscience secures $35M in Series C funding to advance its MSDA test for multiple sclerosis and expand its pipeline for other neurodegenerative diseases.
Key Point: The MSDA test helps clinicians monitor disease activity in MS patients, supporting precision medicine approaches.
Implication: With this funding, Octave aims to revolutionize MS disease management and extend its impact to conditions like Parkinson’s and Alzheimer’s.
🔬 JCR Pharmaceuticals Presents Long-Term Data on Pabinafusp Alfa for MPS II at ICIEM 2025 [6] [5 September 2025]
Source: Business Wire
Context: JCR Pharmaceuticals shared five-year clinical data at ICIEM 2025 on Pabinafusp Alfa for mucopolysaccharidosis type II (MPS II).
Key Point: The data demonstrated sustained neurocognitive benefits, especially when treatment began early in the disease.
Implication: This data could lead to broader adoption of Pabinafusp Alfa as a long-term treatment option for MPS II, especially in pediatric patients.
đź’‰ TG Therapeutics Announces Phase 3 Trial for Subcutaneous BRIUMVI in RMS [7] [8 September 2025]
Source: GlobeNewswire
Context: TG Therapeutics commences enrollment in a Phase 3 trial to evaluate subcutaneous BRIUMVI (ublituximab) in relapsing multiple sclerosis (RMS).
Key Point: The trial will assess whether subcutaneous administration of BRIUMVI offers similar outcomes to the current intravenous form, with a focus on flexibility for patients.
Implication: If successful, subcutaneous BRIUMVI could provide MS patients with more convenient self-administered treatment options.
🧠Migraine and Back-to-School: Experts Share Tips to Reduce Triggers and Support Students [8] [3 September 2025]
Source: GlobeNewswire
Context: The Association of Migraine Disorders shares expert strategies to manage migraine triggers as students return to school.
Key Point: Experts highlight common migraine triggers such as sleep changes, stress, and inconsistent eating habits.
Implication: These insights can help parents, caregivers, and schools support children and teens in minimizing migraine attacks during the school year.
Why It Matters
Patent & Innovation: Silo Pharma’s new patent and Hope Biosciences’ RMAT designation highlight ongoing innovation in PTSD and MS treatments, paving the way for new therapies.
Biosimilars Expansion: Partnerships like Polpharma’s with MS Pharma and Zydus with Synthon promise to increase the availability of affordable MS treatments in multiple global regions.
MS Disease Management: Octave Bioscience’s funding and the trial for subcutaneous BRIUMVI are examples of how precision medicine and flexible administration options are reshaping MS treatment.
Rare Disease Research: JCR Pharmaceuticals’ data on Pabinafusp Alfa for MPS II underscores the growing impact of long-term, gene-targeted therapies for rare neurological diseases.
Migraine Awareness: Raising awareness about migraine triggers during the school year can help prevent and manage migraine attacks for children and teens, improving their quality of life.
📢 Stay Ahead in Neuroscience Research!
✅ Contact LucidQuest at info@lqventures.com for strategic guidance on neuroscience and breakthrough therapies
FAQ
What is SPC-15 and why is its patent important?
SPC-15 is an intranasal treatment for PTSD, and its new patent offers protection and supports clinical trial development, potentially offering a novel treatment option for PTSD patients.
What does RMAT designation mean for Hope Biosciences?
RMAT designation from the FDA fast-tracks development and review for Hope’s stem cell therapy for MS, offering a faster path to market for this innovative treatment.
What is the significance of Polpharma’s partnership with MS Pharma?
This partnership aims to expand access to MS biosimilars in the MENA region, improving affordability and access to essential MS treatments.
How does Pabinafusp Alfa work for MPS II?
Pabinafusp Alfa, a blood-brain barrier-penetrant enzyme replacement therapy, helps improve neurocognitive function in MPS II patients, with long-term data showing positive results.
How could subcutaneous BRIUMVI benefit MS patients?
Subcutaneous BRIUMVI offers MS patients an at-home, self-administered treatment option, providing flexibility compared to the intravenous version.
What are the tips for managing migraine triggers for students?
The Association of Migraine Disorders suggests creating consistent routines, protecting downtime, and addressing common migraine triggers like stress, irregular sleep, and dehydration.
Entities / Keywords
PTSD, Silo Pharma, Hope Biosciences, Regenerative Medicine Advanced Therapy (RMAT), Polpharma Biologics, MS Pharma, Biosimilars, Pabinafusp Alfa, MPS II, Multiple Sclerosis, BRIUMVI, Zydus Lifesciences, Synthon, Octave Bioscience, Neurodegenerative Diseases, Migraine, Migraine Management, FDA, Biosimilars Market, Clinical Trials.
References
Silo Pharma secures Australian patent — GlobeNewswire
Hope Biosciences receives RMAT designation — Multiple Sclerosis News Today
Polpharma-MS Pharma partnership — Business Wire
Zydus and Synthon partner for Ozanimod — PR Newswire
Octave Bioscience Series C funding — Business Wire
JCR Pharmaceuticals data on Pabinafusp Alfa — Business Wire
TG Therapeutics launches Phase 3 BRIUMVI trial — GlobeNewswire